Abstract 438P
Background
Immune checkpoint inhibitors (ICIs) demonstrate efficacy against various cancers by activating the immune response against neoplasia. On the other hand, ICI-related myocarditis, which has a high mortality rate, is known to occur as adverse event. Therefore, safe ICI therapy should be established worldwide. In the present study, we developed a mouse model of ICI-related myocarditis and evaluated the efficacy of vitamin D, which exerts therapeutic effects on autoimmune myocarditis.
Methods
PD-1 knockout (PD-1KO) mice were treated with the myocardial myosin peptide and pertussis toxin to create a mouse model of ICI-related myocarditis. After 21 days of myocardial myosin peptide administration, their hearts were dissected and evaluated for the development of myocarditis. In addition, vitamin D, a candidate drug, was administered to the model mice every other day to evaluate its effect on the severity of myocarditis.
Results
Administering the myocardial myosin peptide to PD-1KO mice resulted in infiltration of inflammatory cells into the myocardial tissue and progressive myocardial fibrosis. Fluorescent immunostaining showed infiltration of CD4⁺ and CD8⁺ T cells in the myocardial tissue. Inflammatory cell infiltration was significantly suppressed in the vitamin D-treated group than in the vehicle group, as was CD4⁺ and CD8⁺ T cell infiltration. There was a trend toward suppression of myocardial fibrosis with vitamin D administration, although without statistical significance.
Conclusions
By administering the myocardial myosin peptide to PD-1KO mice, we generated a simple and reproducible experimental model of ICI-related myocarditis. Furthermore, vitamin D attenuated the infiltration of inflammatory cells and prevented the onset of ICI-related myocarditis in the model mice. The application of vitamin D as a prophylactic agent for ICI-related myocarditis should be investigated in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japan Society for the Promotion of Science.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract